Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab Plus Pemetrexed in Relapsed or Refractory Primary DLBCL of the CNS
NCT05253118Phase 2Active, not recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in diffuse large B-cell lymphoma (DLBCL), sponsored by Seoul National University Hospital. Started Aug 2022; status: active, not recruiting.
02
Drugs
tislelizumab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05253118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05253118.